Tiziana Life Sciences, which is developing antibody therapies to combat NASH, Crohn's disease, MS, and cancer, filed on Thursday with the SEC to raise up to $12 million in an initial public offering.
The London, United Kingdom-based company was founded in 1998 and plans to list on the Nasdaq under the symbol TLSA. Laidlaw & Company (UK) is the sole bookrunner on the deal. No pricing terms were disclosed.
